[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
/in International Publications, Newcastle Disease Virus /von 2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-6Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
/in Hyperthermia, International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2010-08-01 / Surgery 2010 Aug;148(2):325-34[Progress in using Newcastle disease virus for tumor therapy: a review]
/in International Publications, Newcastle Disease Virus /von 2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-6Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer
/in Gastric Cancer, International Publications, Newcastle Disease Virus /von 2010-06-01 / J. Mol. Med. 2010 Jun;88(6):589-96New perspectives in cancer virotherapy: bringing the immune system into play
/in International Publications, Newcastle Disease Virus /von 2010-03-01 / Immunotherapy 2010 Mar;2(2):185-99The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting
/in International Publications, Newcastle Disease Virus /von 2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-99Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
/in International Publications, Newcastle Disease Virus /von 2010-01-25 / Oncogene 2010 Apr;29(15):2205-16The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2010-01-01 / J. Virol. 2010 Jan;84(1):639-46Oncolytic virus therapy for prostate cancer
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de